News

The "King Kong" of weight loss medications, Mounjaro (tirzepatide), is a dual GIP and GLP-1 receptor agonist licensed in the UK for treating type 2 diabetes mellitus and for weight loss. As with any medication affecting pancreatic function, questions have emerged regarding potential links between Mounjaro and pancreatic cancer. Current evidence from clinical trials and regulatory reviews does not establish a causal relationship between tirzepatide and pancreatic malignancy. L

Researchers say daily calorie intake may be up to 10 times more influential than physical activity in weight gain.

You may have heard that Rybelsus is changing doses... RIP 3mg, 7mg & 14mg

A MAJOR review has pitted the big three blockbuster weight management jabs against each other – comparing weight lost and how long users were able to maintain it. There are several weight loss treatments now available in the UK via the NHS and private clinics Scientists compar ed tirzepatide – the active ingredient of Mounjaro – to semaglutide, which is in Wegovy and Ozempic, and liraglutide, that’s in Saxenda. he reviews – published in the gold-standard Cochrane Database of

You may have seen the news over the weekend regarding a UK woman who used "black market" weight loss medication at a local salon for £20 a jab. The drive for weight loss medications has created a boom in black market sales of medications.

The MHRA has raided & shut down a factory in the UK producing fake Mounjaro (Tirzepatide) and the yet-to-be-released Retatrutide.

The vast majority of patients on Mounjaro currently pay for it privately but some patients can get it on the NHS...

Wegovy mimics the hormone GLP-1, acting on the brain to reduce appetite and slow digestion. Contrave (naltrexone/bupropion) affects brain reward and craving pathways, which can reduce emotional eating but doesn’t directly target satiety hormones. How Wegovy works Wegovy (semaglutide 2.4 mg weekly) is a GLP-1 receptor agonist. It mimics a natural gut hormone called GLP-1, which signals to the brain that you are full, slows down stomach emptying, and enhances insulin release wh

Nausea? Hair loss? Headaches Acid reflux? Sulphur burps? These can be some of the most common side effects when using weight loss medications such as Mounjaro and Wegovy. We can help.

Since both contain semaglutide, their side-effect profiles are similar — most commonly nausea, vomiting, and diarrhoea. Wegovy uses a...

On the NHS, costs are set through commercial arrangements and are not always public, while in private practice the listed prices for...

In major STEP trials, Wegovy led to about 15% weight loss over 68 weeks. Contrave (called Mysimba in the UK) generally achieves around 6–9% across pivotal studies. This means semaglutide tends to provide greater weight reduction than naltrexone/bupropion combinations. Two very different approaches Although both Wegovy and Contrave are prescribed for weight management, they work in completely different ways. Wegovy contains semaglutide, a GLP-1 receptor agonist that reduces ap

Yes, Wegovy and metformin are often used together in people with type 2 diabetes, and no special dose adjustment is typically required. They work differently: Wegovy (a GLP-1 receptor agonist) reduces appetite, slows stomach emptying, and boosts insulin release, while metformin mainly reduces glucose production in the liver and improves insulin sensitivity. Why these medicines are combined Doctors frequently prescribe Wegovy (semaglutide) alongside metformin, particularly in

Combination weight loss medications aren’t routine in UK services because evidence for stacking treatments is limited and side-effect...

You may have seen the news today... The price of ‘King Kong’ fat jab Mounjaro will almost triple from September adding a potential £2,704 a year to the cost of the drug.

Weight loss medicines have always been subject to close regulatory scrutiny in the UK. Questions about safety, long-term outcomes, and marketing claims have historically made approvals slow and complex. The arrival of Wegovy, however, marked a significant shift. With strong trial data and NICE endorsement, semaglutide has not only reshaped consumer demand but also influenced how regulators and policymakers approach the entire category of weight loss pharmaceuticals. Changes i

Pharmaceutical breakthroughs rarely stand alone. Behind every new treatment lies a network of research teams, healthcare providers, regulators, and increasingly, technology firms. Strategic collaborations are the glue that connects these players, accelerating development and improving delivery. With the arrival of Wegovy, the importance of collaboration in the UK weight loss sector has become even clearer. The medicine’s impact has extended beyond patients and clinics, sparki

Trials of a daily obesity pill have shown it can help patients lose around 12% of their body weight over 72 weeks. New weight loss pill...

The marketing of weight loss products in the UK has changed dramatically in recent years. Once dominated by glossy ads, celebrity...

The weight-loss pharmaceutical industry in the UK has long been a challenging space for investors. Products like orlistat offered modest returns, and consumer interest often shifted toward lifestyle fads rather than prescriptions. But Wegovy has changed the calculus. With clinical results that set a new benchmark and NHS endorsement signalling credibility, investors are paying closer attention. Capital is flowing into the sector at levels not seen before, reshaping expectatio